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Background: Seventy percent of women in Scotland have at least one baby, making pregnancy an opportunity to
help most young women quit smoking before their own health is irreparably compromised. By quitting during
pregnancy their infants will be protected from miscarriage and still birth as well as low birth weight, asthma,
attention deficit disorder and adult cardiovascular disease. In the UK, the NICE guidelines: ‘How to stop smoking in
pregnancy and following childbirth’ (June 2010) highlighted that little evidence exists in the literature to confirm
the efficacy of financial incentives to help pregnant smokers to quit. Its first research recommendation was to
determine: Within a UK context, are incentives an acceptable, effective and cost-effective way to help pregnant
women who smoke to quit?
Design and methods: This study is a phase II exploratory individually randomized controlled trial comparing
standard care for pregnant smokers with standard care plus the additional offer of financial voucher incentives to
engage with specialist cessation services and/or to quit smoking during pregnancy.
Participants (n = 600) will be pregnant smokers identified at maternity booking who, when contacted by specialist
cessation services, agree to having their details passed to the NHS Smokefree Pregnancy Study Helpline to discuss
the trial. The NHS Smokefree Pregnancy Study Helpline will be responsible for telephone consent and follow-up in
late pregnancy. The primary outcome will be self reported smoking in late pregnancy verified by cotinine
measurement. An economic evaluation will refine cost data collection and assess potential cost-effectiveness while
qualitative research interviews with clients and health professionals will assess the level of acceptance of this form
of incentive payment. The research questions are: What is the likely therapeutic efficacy? Are incentives potentially
cost-effective? Is individual randomization an efficient trial design without introducing outcome bias? Can
incentives be introduced in a way that is feasible and acceptable?
Discussion: This phase II trial will establish a workable design to reduce the risks associated with a future definitive
phase III multicenter randomized controlled trial and establish a framework to assess the costs and benefits of
financial incentives to help pregnant smokers to quit.
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Smoking during pregnancy increases miscarriage and
stillbirth, accounting for up to 4000 UK deaths annu-
ally, and pre-term birth and low birth weight leading
to perinatal morbidity [1]. A third of excess stillbirths
and post-natal deaths associated with living in deprived
areas are explained by smoking during pregnancy [2].
In Scotland 70% of women have a baby [3], making
pregnancy an opportunity to help most women quit
before their health is permanently compromised. In
2009, 24% of women booking for maternity care self-
reported as current smokers [4]. Less than 1 in 20 of
these women quit [5]. A study in the USA [6] in 2001
calculated the additional first year costs to health ser-
vices as $1200 per smoker. Smoking is a major pre-
ventable cause of premature mortality for the mother,
and lifelong benefits of quitting for children include
reduced incidence of asthma and attention deficit
disorder.
Following the 1998 White paper ‘Smoking Kills’,
evidence-based National Health Service (NHS) smoking
cessation services using behavioral support were devel-
oped [7-9] and now exist throughout Scotland [5]. Most
of these services aim to provide tailored support (referred
to in this paper as NHS Smokefree Pregnancy Services -
NSPS) to pregnant women on a one-to-one basis, and
evidence suggests that such interventions during preg-
nancy are effective [10]. Nicotine replacement therapy
(NRT) is also offered, although its efficacy in pregnancy
is not yet clear [10]. In Greater Glasgow & Clyde
(GG&C), with 15,000 pregnancies per year, pregnant
smokers identified at maternity booking are currently
routinely referred to the NSPS on an ‘opt-out’ basis,
without consent for transfer of contact information [7].
This practice is in keeping with the recent National In-
stitute for health and Clinical Excellence (NICE) guide-
lines in the UK [11]. Women are then contacted by
NSPS advisers who ask if they would like to quit and
offer a face-to-face appointment in a clinic or home
setting. If the client attends they set a quit date and a
risk assessment for use of NRT during pregnancy is
performed.
Participation figures for areas with recognized special-
ist smoking cessation in pregnancy services from a
Scotland-wide audit are shown below [5]:
A. Estimated number of pregnant smokers at
maternity booking [12], 8170 (100%).
B. Smokers identified by self report at routine booking
questionnaire, 6128 (75%).
C. Smokers referred to specialist pregnancy cessation
services, 3188 (39%).
D. Smokers engaged - face to face contact with
specialist cessation service, 763 (10%)a.E. Smokers who ‘set a quit date’, 779 (10%).
F. Smokers who had quit 4 weeks later, 236 (3%).
aDifferent denominator.
In Scotland, all women who book for maternity care
are asked if they are current, former or never smokers (B
above). At present 25% deny their habit (A to B) [12].
This problem is being addressed by routinely testing all
pregnant women at maternity booking for carbon mon-
oxide using a breath test [11]. Only half were referred (B
to C) due to busy clinics and perceived client disapproval.
Only 10% reached specialist cessation services such as
those available in Glasgow (D). Nearly all of these ‘set a
quit date’ (E) and 3 in 10 (F) quit. Some improvement (E
to F) may be possible as 4 in 10 quit [13] with support
from NHS cessation services in other parts of the UK.
Incentives are thought to increase participation and en-
gagement [14,15], retention [16,17], and cessation [15-
18]. If offered incentives, women who deny smoking may
report as current smokers (A to B). Clients may self-refer
or ask to be referred (B to C). With incentives, a greater
proportion may engage (C to D) [5]. Improvement in the
numbers quitting (D to F) will follow. In Scotland, when
more pregnant smokers were referred, more engaged and
more quit [5].
A 2009 Cochrane systematic review of interventions
for promoting smoking cessation during pregnancy [10]
asked: Do interventions improve quit rates? Are some
interventions better than others? Figure 1 is a funnel plot
describing the outcome from all included trials showing
intervention better than control to the left. Fewer small
trials on the right (control better than intervention) indi-
cates some publication bias so the pooled risk ratio 0.94
may overestimate any combined positive effect. The four
incentives trials showed significantly better outcomes
than other interventions: pooled risk ratio 0.76 (95% con-
fidence interval (CI) 0.71 to 0.91).
However, the incentives trials are all from the USA.
The first trial was conducted 25 years ago and only
included incentives as a minor part of an extensive inter-
vention. Other incentives trials were small [16-18] and
did not have a ‘no incentive’ control group [17,18]. None
attempted to measure change in participation or engage-
ment with an intervention. The NICE guidelines [11]
issued in June 2010 highlighted that little evidence exists
in the literature to confirm the efficacy of financial incen-
tives to help pregnant smokers to quit. Its first research
recommendation was: “Within a UK context, are incen-
tives an acceptable, effective and cost-effective way to
help pregnant women who smoke to quit?”
Since 2007, NHS Tayside in Scotland has piloted an
incentives model - £12.50 per week of supermarket vou-
chers - to reward smoking cessation from quit date to 3
months after birth. The total payment for quitters is up
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Figure 1 Funnel plot. Figure 1 is a funnel plot of all studies
included in the Cochrane systematic review: interventions for
promoting smoking cessation during pregnancy [10]. The overall risk
ratio for smoking cessation in each study is plotted on the x axis.
The sample size of each study is plotted on the y axis. The plot
illustrates possible publication bias with a gap caused by ‘missing’
studies upsetting the symmetry on the right hand side of the figure,
indicating that small negative studies may not have reached the
point of publication. Diamond shaped symbols indicate individual
randomization whereas square symbols indicate that cluster
randomization was used in the trial. The four black diamond shapes
on the left side represent the four incentives trials included in the
review. The dashed vertical line crosses the x axis at the weighted
mean risk ratio of smoking reduction in all studies comparing
intervention with control – 0.94 (95 % confidence interval 0.93
to 0.95).
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control group but the number of women accessing cessa-
tion support has increased since incentives were intro-
duced [19]. Women access the service at their local
pharmacies, which provide NRT as well as support and
validate whether the client has stopped smoking. This in-
formation initiates a payment onto a store card. During
2009, 169 (14%) of about 1200 pregnant smokers [5]
joined the program (the equivalent of engagement) and
94 (8%) women had quit smoking 4 weeks later; 42 were
still quit at delivery (personal communication, Andrew
Radley). This cessation rate is higher than those obtained
by other Scottish smoking cessation in pregnancy ser-
vices, where the average quit rate at 4 weeks is 3%, and
the best 5% [5]. A feasibility study for an incentives trial
in Glasgow reported in January 2009 [20]. It explored
how the Tayside program could be adapted for service
configuration in Glasgow. The feasibility study provided
the foundation for development of this trial.
This phase II trial will provide the tools required to
run a future appropriately powered definitive phase III
multicenter randomized controlled trial. The aim of that
future phase III trial will be to establish whether or not
incentives increase engagement with services, quit
attempts and successful cessation to provide a more
cost-effective pregnancy smoking cessation service
model generalizable to the whole UK and beyond.Design and methodology
Population
In 2010 there were 58,051 births in Scotland with 14,155
(24%) to mothers resident in NHS GG&C Health Board
area. Twenty-six percent of births in Scotland are to
women who live in the most deprived quintile, whereas
in GG&C it is 44% [21]. Of the most deprived women
who were asked, 35% self reported that they smoked at
maternity booking compared with 7.1% of the least
deprived [22]. Overall, in GG&C 25% of women self re-
port as current smokers at maternity booking.
Design
The study is designed as a phase II single blinded (out-
come assessor blind to randomization status at follow-
up telephone contact) individually randomized con-
trolled trial. The procedures are illustrated schematically
in Figure 2 and detailed in the text.
Research questions
Trial
1. What is the likely therapeutic efficacy of financial
incentives to encourage women to attend specialist
cessation services, to set a quit date, to quit smoking
and be abstinent at 34 to 38 weeks gestation towards
the end of pregnancy?
2. Is individual randomization an efficient trial design
without compromising validity through bias due to
differential follow-up of disaffected control arm
participants?
Health economic study
3. Are incentives potentially a cost-effective means of
helping pregnant women to stop smoking?
Qualitative study
4. Can incentives be introduced in a way that is
feasible and acceptable to women and service
providers and are there any unintended
consequences?
NHS Smokefree Pregnancy Services Greater Glasgow &
Clyde Health Board area
At their maternity booking appointment pregnant
women in NHS GG&C are asked for consent for screen-
ing which includes procedures to identify and offer treat-
ment to current smokers – self report and routine
carbon monoxide breath test with follow-up by NSPS.
All women with either a carbon monoxide level of 5 ppm
and above or self reported as current smokers (at least 1
cigarette in the last week) are notified to NSPS using a
15,000 pregnancies during 12 months in study area4 
600 smokers consent for incentives9 trial during 12 months 
5,000 smokers5, 12
3,000 self reported smokers  
500 not contactable 
by  telephone5,7
600-900 decline consent9
SECONDARY OUTCOMES 
Proportion who set a quit 
300 control smokers  
Standard care 
No incentive offered 
Estimated from 
Tayside service  
207 (69%) 
10,000 non-smokers
             300 intervention smokers 
Standard care + 
Incentive offered 
Proportion who have quit 4 weeks 
l
NSPS telephone all smokers and offer support to quit. Trial information will be given and verbal 
permission sought for contact detail transfer to NHS Smokefree Pregnancy Study Helpline
Estimated from 
Glasgow data  
174 (58%)5,7
 54 (18%)5,7103(34%
2000 smokers’ details passed to NHS Smokefree Pregnancy Study Helpline
500 decline permission to pass 
information to NHS Smokefree 
1500 smokers contacted by NHS Smokefree Pregnancy Study Helpline  
500 not contactable by telephone5,7
Identify and refer smokers All women asked (current, former, never smoker) 
at maternity booking. All results sent to the NHS Smokefree Pregnancy Service (NSPS)
PRIMARY OUTCOME 
Proportion quit at late pregnancy
SECONDARY OUTCOME 
                     Birth weight  
12-27(4-9%)9,10
- late pregnancy
2000 smokers not identified5,7
Figure 2 Flow diagram for Cessation in Pregnancy Incentives Trial (CPIT). Figure 2 projects the flow of pregnant women through the trial
over a 12-month period. In the NHS Greater Glasgow & Clyde study area, 15,000 pregnancies are recorded at maternity booking; 5,000 are to
smokers, some who conceal their habit, and 3,000 are identified at maternity booking by self-report as current smokers. Their information is
routinely passed to NHS Smokefree Pregnancy Services (NSPS) using an automated system. Attempt is made to contact all self reported smokers.
We estimate that 500 will not be contactable by NSPS and that 500 will decline permission for their details to be passed to the NHS Smokefree
Pregnancy Study Helpline (Study Helpline). Once details have been passed, 500 will not be contactable leaving 1,500 contacted by the Study
Helpline. We expect that 600 to 900 will decline consent leaving 600 to 900 who agree to enroll in the study over 12 months. Of these, 300 will
be randomly allocated to the intervention group to be offered incentive payments as well as standard care to stop smoking during pregnancy
and 300 will be randomly allocated to receive the offer of standard care without incentive payments to quit smoking.
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women by telephone and offer a smoking cessation coun-
seling service which utilizes ‘Withdrawal Oriented Ther-
apy’ [23]. Support includes a face-to-face appointment,
weekly telephone support for 4 weeks and the offer of
NRT dispensed by local pharmacies free of charge to
support a quit attempt for up to 12 weeks.
Trial inclusion criteria
Participants must satisfy the following criteria to be
included in the study:
 age at least 16 years and pregnant less than 24
weeks gestation at maternity booking. self report as current smokers.
 have a carbon monoxide breath test result of 7 ppm
or greater - NICE guideline level for referral of
pregnant smokers – PH26 [11].
 live in the NHS GG&C Health Board area.
 give permission for their contact details to be passed
to NHS Smokefree Pregnancy Study Helpline.
 be able to understand and speak English in order to
provide verbal telephone consent to take part in
the trial.
Screening
Early in the first telephone contact call from an NSPS
adviser, eligible smokers will be given information about
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contact details to be passed to the NHS Smokefree Preg-
nancy Study Helpline so that formal trial telephone con-
sent procedures can take place. The Caldicott Guardian
has approved this verbal permission required to pass this
contact information. Those who give permission for
contact details to be passed will be sent a letter and a
trial information sheet outlining the nature and import-
ance of the trial. The NSPS adviser will then continue
with standard treatment and follow-up procedures.
Recruitment
We will enroll 600 eligible pregnant smokers to this
phase II trial over a 12 month period. This is illustrated
in Figure 2 based on existing throughput from local ser-
vices in the study area and is a conservative time period
taking into account smokers not identified or referred
and those who decline consent to take part in the incen-
tives trial. We expect high enrollment of eligible smokers
and that knowledge of the trial will increase eligible smo-
kers who agree to consider cessation during this preg-
nancy and consent to take part in the trial.
Consent and randomization procedure
At least 7 days after the first NSPS contact call, eligible
smokers who allow their contact details to be passed on
will be contacted by the Helpline to undergo formal con-
sent procedures. Telephone contact will be attempted on
three occasions at the time slot preferred by the client -
weekday, evening or weekend - after which no further
attempts at enrollment will be made. During the consent
call potential participants will be fully informed about
the nature and relevance of the trial, and exactly what
will be involved if they agree to take part. Early in the
consent call potential participants will be asked to pro-
vide information not asked for at maternity booking in-
cluding questions measuring level of addiction to
nicotine and partner smoking habits. Audio recordings
of the consent process will be stored in accordance with
Good Clinical Practice guidelines. Eligible smokers who
consent to take part in the trial will be sent a written
copy of their consent form. Individuals who give
informed consent will be enrolled in the trial and rando-
mized. The random allocation will be fed back to the par-
ticipant. The Helpline adviser cannot influence or predict
the random allocation which is integrated into the clin-
ical information system. It will also provide a concealed
(not available to the NHS Smokefree Pregnancy Study
Helpline adviser during the consent call) random date
between 34 and 38 weeks gestation for this pregnancy
when the Helpline will contact the participant again to
ascertain the primary outcome measure of self reported
smoking during the last 8 weeks which will be corrobo-
rated by cotinine measurement.Baseline (pre-randomization) data collection
Identification and contact
Patient name, address, full postcode, telephone numbers
(home, mobile, office).
Best time to call, best number, estimated date of deliv-
ery, name of referrer, General Practitioner name.
Eligibility criteria
Self reported smoking status at maternity booking, car-
bon monoxide breath test level at maternity booking,
date of carbon monoxide reading, age at first telephone
contact, English speaking, gestation at booking, consent,
copy of consent form sent.
Smoking addiction level and other
Fagerstrom questions [24] score out of 10, parity, partner
smokes.
Randomization
Randomization will be embedded within the trial data-
base. The random allocation sequence will be generated
by the Robertson Centre for Biostatistics, University of
Glasgow (part of the Glasgow Clinical Trials Unit), using
the method of randomized permuted blocks, with a block
length of 4. In addition, a random date between 34 and
38 weeks gestation for each pregnancy will be generated
as the date for primary outcome data collection. Patient
details will be entered prior to randomization so that the
allocation is concealed from Helpline staff and the client
until after the patient has been enrolled in the study and
provided baseline information. The participant will be
informed of their random allocation group towards the
end of the Helpline ‘trial consent’ telephone contact call,
but will not be informed of the date when their primary
outcome data will be collected.
For a period during trial recruitment an extra consent
question will be ‘turned on’ during the consent call ask-
ing clients also to consent to being contacted by trial staff
for the purposes of one-to-one interviews to fulfill quali-
tative aspects of this research trial.
Voucher incentive payments Those allocated to the
intervention group will be offered financial incentives -
Love2Shop vouchers - that can be redeemed in a wide
array of UK shops but not used for the purchase of cigar-
ettes or alcohol. The total amount available is £400 if
women remain abstinent at each monitoring point.
Women will receive incentive payments outlined below:
£50 for attending a face-to-face appointment with their
NSPS adviser and setting a quit date;
£50 if quit 4 weeks after their quit date corroborated
by a carbon monoxide breath test result less than 10
ppm collected by a research nurse;
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monoxide breath test collected by a research nurse;
£200 if they self report quit for at least 2 months when
contacted for primary outcome assessment by the Help-
line at 34 to 38 weeks gestation. This will be corrobo-
rated by a carbon monoxide breath test result less than
10 ppm collected by a research nurse.
Trial participation payments
In order to minimize loss to follow-up, particularly
among control participants, £25 will be given to all parti-
cipants if they provide primary outcome information
(and required samples to corroborate abstinence) at 34
and 38 weeks gestation.
Quantitative data collection
Primary outcome
Smoking status at 34 to 38 weeks gestation, towards the
end of pregnancy. Follow-up telephone contact will be
attempted by NHS Smokefree Pregnancy Study Helpline
at a random date between 34 and 38 weeks gestation
allocated at the time of the initial randomization. A pa-
tient record check will be made by the NHS Smokefree
Pregnancy Service administrator looking for stillbirth,
miscarriage or patient death the week prior to the tele-
phone contact at 34 to 38 weeks gestation. Miscarriage
or stillbirth may not preclude a woman from receiving
vouchers if they are in the intervention group.
Three attempts will be made to contact participants. If
no contact is possible the participants will be followed up
by the research nurse either by telephone or by a home
visit after a contact detail check with the participant’s
General Practitioner. If participants self report as non-
smokers then a research nurse will make an appointment
to collect urine and saliva for cotinine estimation (as well
as a breath test for carbon monoxide to trigger the incen-
tive payment).
If successful contact is made, the participant will be
asked: ‘Have you smoked in the last 8 weeks?’ If yes ‘Have
you smoked more than 5 cigarettes in that time?’ Self re-
port will be corroborated by cotinine estimation on saliva
and urine. Urine (cut-off 44.7 ng/ml) or saliva (cut-off
14.2 ng/ml) cotinine will be measured by ABS laborator-
ies limited (abslabs@biopark.org.uk).
The important aspect of the primary outcome for this
phase II trial is the proportion of participants success-
fully followed up from the intervention but particularly
the control group. If acceptable levels (about 90%) of
participants can be successfully followed up with a simi-
lar proportion in the intervention and control groups,
then individual randomization can be accepted as a de-
sign choice for a future phase III trial that does not pro-
duce significant bias due to differential loss to follow-up
between groups.Secondary outcomes
Engagement with specialist pregnancy cessation ser-
vices is achieved if the participant arrives at a first face-
to-face appointment with the NSPS adviser and sets a
quit date.
Quit at 4 weeks after quit date will be ascertained with
the question ‘Have you smoked in the last 2 weeks, even
a puff?’ at routine telephone contact by the NSPS adviser.
This will be corroborated by a carbon monoxide breath
test collected at routine pharmacy visits to collect NRT.
These data will be available from both intervention and
control groups.
Birth weight The best methods to gather these data effi-
ciently will be examined and tested. Maternal height and
weight is recorded routinely at maternity booking and
will be used to help clarify birth weight differences dur-
ing data analysis. Babies of smokers are on average 300 g
(10%) lighter than babies born to non-smokers [25].
Unintended consequences We do not anticipate the
provision of extra finance to participants will have any
adverse effects. We are not systematically documenting
adverse events that happen during pregnancy. We are,
however, examining unintended consequences formally
using in-depth interviews with a sample of enrolled cli-
ents. Such possible unintended consequences include, for
instance, taking up smoking prior to maternity booking
in order to receive incentive payments by stopping
afterwards.
Health economics Economic analysis will be undertaken
alongside the trial, utilizing the costs, resource use and
effectiveness data generated within the trial. For example,
the cost of financial incentives, NRT, service delivery,
and so on, will be collected and combined with resource
use data. The number of quitters at the end of the trial
will be combined with the cost data to calculate the in-
cremental cost per late pregnancy quitter. The secondary
outcome measure of child birth weight is strongly related
to health care costs. Birth weight will be used to deter-
mine any difference in weight and therefore health care
costs between neonates of mothers in the intervention
group compared to mothers allocated to the control
group.
Health economic assessment A within-trial analysis
will explore the incremental cost per late pregnancy
quitter, followed by a longer term analysis incorporating
the cost to the NHS of any difference in birth weight
due to smoking and looking at potential lifetime
quality-adjusted life year (QALY) gains to the mother
and child.
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[26] (which uses a Markov design to model the lifetime
likelihood and impact of cessation, expressing the long-
term health benefits of quitting smoking in terms of
QALYs saved and the potential long-term reduced costs
to the health service of cessation) will be used. This
model will be adapted to incorporate the trial informa-
tion and relevant published evidence in order to capture
the short and longer term costs and health gains for both
mother and child of smoking cessation during pregnancy.
The outcomes will be presented in terms of the incre-
mental cost per QALY saved. The model will be analyzed
probabilistically in order to characterize uncertainty in
the parameters, and estimate confidence limits around
the cost and effectiveness outcomes. Areas of uncertainty
identified within the model will help inform decisions
about the potential value of future research. This model
will ascertain whether any (and what type of ) data should
be collected to inform a more definitive economic
evaluation and contribute to the optimal design of a
Phase III trial.
Analysis
Analysis of outcomes will be by intention-to-treat, as the
intervention is the offer of financial incentives to engage
with cessation services and to quit smoking.
Differences by subgroup (maternity unit, deprivation
score, age group, and so on) will be explored.
Sample size
The study is not designed to be able to detect a specified
difference in the primary outcome of quit rate at 34 to 38
weeks gestation. The main objective is to inform the
feasibility and design of a future definitive trial. How-
ever, assuming a quit rate of 4% in the usual care arm
of the study, then with 600 participants the study will
have 90% power to detect an increase in quit rates to
11.4%, or 80% power to detect an increase to 10.2%,
based on a continuity-corrected χ2 test at a 5% level of
significance. Even if these outcome rates were achieved
in this study, a Phase III study would be required to
demonstrate that the intervention can be effective in
other settings.
Overview of qualitative research components
Qualitative outcomes
The qualitative research will take the form of a process
evaluation designed to inform aspects of the proposed
trial. It will contribute to:
 assessing the feasibility and acceptability to women
and service providers of using incentives to promote
cessation during pregnancy (including identification
of barriers and facilitators). identifying any unintended consequences of
participation.
 exploring responses to randomization approaches
 providing guidance on how the intervention might
be modified for the Phase III randomized
controlled trial.
Interviews will be conducted with small samples of (i)
pregnant women and (ii) relevant professionals by
researchers at Stirling University led by Susan MacAs-
kill. This work will expand on qualitative research
already undertaken with clients and professionals in re-
lation to ‘Give it up for Baby’, the incentives scheme in
Tayside [19].
Qualitative interviews will be conducted with pregnant
women and professionals using semi-structured topic
guides developed in line with the research aims. Topics
will not be explored in a prescriptive manner but as part
of an open discussion. This flexible format will enable
additional salient topics and insights to emerge. In broad
terms, the focus for the different respondent groups will
be as follows:
One-to-one interviews with pregnant women (all of
whom have engaged with the service) will explore views
on issues around the delivery and promotion of the ces-
sation service, response to incentive features and
randomization, and any unintended consequences. Those
interviewed prior to the trial start will be asked to re-
spond to the concept of the incentives and the trial ele-
ments in addition to routine service elements, whilst
those interviewed during the trial will also be asked to re-
spond to these elements but based on personal experi-
ence of the trial.
Focus group interviews with pregnant women (smokers/
recent ex-smokers) interviewed before the trial starts will
also explore views on issues around the delivery and pro-
motion of the cessation service, response to incentive
features and randomization, and any unintended conse-
quences. Responses can incorporate personal experi-
ences, but will largely be based on response to the
concept of these issues.
Interviews with professionals will explore issues
around implementation of the intervention and the
trial elements, identify challenges and ways they have
been overcome, and perceived response among
participants.
With the participants’ consent, all interviews and
focus group discussions will be recorded as digital
audio files, which will then be transcribed in full for
thematic analysis. Transcripts will be organized using
a thematic framework based on topics specified in
the topic guide and emerging themes identified
through a process of familiarization with transcript
texts.
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Prior to the trial starting, up to 10 pregnant smokers will
be recruited from amongst those already in contact with
NSPS in Glasgow. Women will be informed about the
study by specialist advisers on smoking in pregnancy
and asked if they are interested in participating. Those
interested will be provided with an information sheet
and will be asked if their details can be passed to the
lead qualitative researcher. Those who consent to their
details being sent on will be contacted by phone to ad-
dress any queries and to arrange an interview time and
place. Alternatively, if they consent at the time of the
initial information being provided, interviews can be
conducted following their second session with the spe-
cialist advisor. Interviews will be conducted face to face
and written consent obtained.
In addition, two one-off focus groups (4 to 8 respon-
dents each) with pregnant women (incorporating
smokers/recent ex-smokers) will be conducted. Women
will be recruited by the researcher through ante-natal
classes or other appropriate groups attended by pregnant
women and again explanations will be given and consent
sought to participate.
During the trial an additional 20 women will be inter-
viewed after they have engaged with the trial. These will
be different women from those interviewed prior to the
trial. Pregnant smokers will be informed about this part
of the study by the NHS Smokefree Pregnancy Study
Helpline and asked if they are interested in participating
in the interviews as part of the initial consent process.
Details of those who express an interest and consent to
be contacted will be passed to the research team. Points
at which individuals will be interviewed will be spread
across the pregnancy (that is, at around 4, 12 and 20
weeks post-set quit date). Mechanisms will be in place to
ensure there are no contraindications prior to re-
contacting those to be interviewed in later pregnancy
(for example, any adverse pregnancy outcomes such as
miscarriage). Both continued participants and those who
have dropped-out will be included in the sample.
Respondents will be recruited from two hub areas in
Glasgow and Clyde. All pregnant women participants
will be offered £20 in recognition of their contribution to
the study.
Professionals will also be interviewed as part of the
qualitative study. They will be approached through ap-
propriate organizational structures, facilitated by study
co-applicants. Information sheets will be provided and
consent obtained. The professional sample is intended to
reflect a range of perspectives on implementation and
the conduct of the trial. They will therefore include:
pregnancy smoking cessation advisor(s) and manager,
Clinical Research Facility nurse(s), interviews with the
NHS Stop Smoking Study Helpline staff/managers,community midwives and manager, and community
pharmacy facilitator(s). Professionals will be interviewed
by telephone or face to face.
Discussion
In Scotland, up to a third of pregnant women smoke
throughout pregnancy. This is responsible for a third of
miscarriages, still births and sudden infant deaths during
the first year of life. There would be significant long-term
health gains for mother and child if smokers quit during
pregnancy. At present, less than 10% of pregnant smo-
kers take up the offer of free smoking cessation services
and only 3% quit during pregnancy. Modest incentive
payments to engage with cessation services and/or to
quit smoking may provide a substantial benefit by de-
creasing pregnancy health care costs and first-year health
care costs. If women stay smoke-free, long-term health
care costs will be substantially reduced. The results of
this phase II trial will reduce the risks associated with
funding a definitive phase III multicenter trial. The phase
III trial will examine the costs and benefits of providing
financial incentive payments for smoking cessation dur-
ing pregnancy.
Ethics approval
Ethics approval was received from West of Scotland
REC2 on 25 May 2011.
Caldicott guardian approval was given on 3 February
2011 to allow NSPS GG&C to pass information to the
NHS Smokefree Pregnancy Study Helpline if the client
gives verbal permission that contact details can be
passed.
A major amendment to the trial protocol was approved
on 6 March 2012 to allow use of anonymized qualitative
interview data by the Health Technology Assessment
Programme 10/31/02 BIBS: Benefits of Incentives for
Breastfeeding and Smoking cessation: A platform study
for a trial.
Trial organization
Trial Steering Committee
The overall scientific aspects of the project will be mana-
ged by a Steering Committee. The Steering Committee
will include the investigators above. The Steering Com-
mittee will take all executive decisions.
The responsibility of the Steering Committee is to en-
sure the scientific integrity and quality of the project. To
achieve this, the specific responsibilities of the Steering
Committee include: maintaining adherence to the study
protocol; approving changes to study protocol if
required; reviewing quality assurance indicators; moni-
toring study recruitment and the overall study timetable;
advising, as required, on specific scientific items that may
arise; compliance with legislation; adherence to research
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and dissemination strategies.
The Steering Committee will meet every 6 months.Project Management Group
A Project Management Group (comprising as required
principal investigators, a trial manager, a trial administra-
tor, a senior manager from NSPS, a data manager from
NHS Research and Development, a statistician, a senior
representative from NHS Stop Smoking Study Helpline,
a senior manager from NHS GG&C Research and Devel-
opment, a health economist, a senior qualitative re-
searcher) will run the trial on a day-to-day basis to
ensure the smooth operation of the project. Review
meetings will be held with other members of the team as
appropriate.
The responsibilities of the Project Management Group
include: establishing and monitoring recruitment of par-
ticipants; distributing and supplying data collection
forms and other appropriate documentation for the trial;
data collection and management; data entry and clean-
ing; data analysis; organizing and servicing the Trial
Steering Committee.Data Monitoring Committee
An independent Data Monitoring Committee will not be
established as adverse events related to the financial
incentives intervention are not envisaged and are not
being systematically collected.Data Co-ordinating Centre
The Data Co-ordinating Centre will be based at the
Paediatric Epidemiology and Community Health Unit,
Glasgow University. The responsibilities of the Data Co-
ordinating Centre are to set up and run systems for data
entry, data verification and the checking of errors and
overdue data reports.Callcredit plc
Callcredit plc, Leeds UK, will design and build the web
based portal for data entry comprising the main Elec-
tronic Data Capture system. This system will allow NHS
and research staff to enter data in a timely fashion trig-
gering voucher incentive payments dispatched by
Callcredit.NHS Stop Smoking Study Helpline
NHS Stop Smoking Study Helpline will provide call
centre services: the consent call for participant en-
rollment, and the final call to determine the pri-
mary outcome (self reported smoking at 34 to 38
weeks gestation).NHS Research and Development Glasgow & Clyde
NHS Research and Development are supporting this trial
by providing extra research nursing support for partici-
pant enrollment and follow-up and project assistance for
data entry.
The Robertson Centre for Biostatistics, University
of Glasgow
The Robertson Centre is part of the Glasgow Clinical
Trials Unit, and will provide statistical analysis and
reporting for the study.
NHS Smoking in Pregnancy Services
NSPS GG&C are discussing the trial with participants
and asking permission for contact data to be passed out-
with the NHS to The Listening Company Glasgow
Scotland (a call centre with extensive experience working
with the NHS and who are known for the trial as the
NHS Stop Smoking Study Helpline) for the consent call.
NSPS staff are providing an encrypted list of potential
participants to the NHS Stop Smoking Study Helpline on
a weekly basis. They are providing cost data for the eco-
nomic analysis.
Publication policy
The primary results of the trial will be published with
authorship in relation to specific participation in the
study, with the name order to be presented by the princi-
pal investigators for consideration by the Trial Steering
Committee. Suggested revisions in order of authors
should meet with the approval of the principal investiga-
tors. Publications in specific areas of the study or on
methodological aspects can be led by co-investigators in
their area of expertise subject to approval by the Trial
Steering Committee and the principal investigators. The
requirements for authorship will follow recommended
practice in journal guidelines.
Confidentiality
Encryption defined by NHS GG&C security management
will be in place to pass data for potential participants
from NSPS to NHS Smokefree Pregnancy Study Help-
line, a process agreed by the Caldicott Guardian. Both
NHS Smokefree Pregnancy Study Helpline and CallCre-
dit plc have long histories of managing Government-
related services and are able to demonstrate their
commitment to data security and quality management
through their ISO27001 and ISO9001 accreditations.
Their ISO27001 accredited Information Security Man-
agement Systems demand that all of their systems and
processes are maintained with confidentiality, integrity
and availability of data at the core. In addition both com-
panies are ISO9001 accredited, the internationally recog-
nized standard for Quality Management Systems. During
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Trial status
Recruitment started in December 2011. On 9 june 2012,
199 of 600 were enrolled in the trial.
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